title: Favorable outcome in a child with EBV-negative aggressive NK cell leukemia.
abstract: Aggressive natural killer cell leukemia (ANKL) is a rare malignant disorder of mature NK cells frequently associated with Epstein-Barr virus (EBV). This malignancy is typically treated with intensive remission induction chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT). EBV-negative ANKL and childhood ANKL, however, are not well defined and the optimal therapeutic strategy in these cases is poorly understood. Here, we present a unique pediatric EBV-negative ANKL patient who achieved a successful treatment outcome after intensified ALL type chemotherapy without allogeneic HSCT.
authors.affiliation: Department of Pediatrics, Haeundae Paik Hospital, Inje University College of Medicine, 1435 Jwa-dong, Haeundae-gu, Busan 612-862, Korea. jeonga95@gmail.com
authors.forename: Jeong A
authors.initials: JA
authors.lastname: Park
authors.forename: Kyung Ran
authors.initials: KR
authors.lastname: Jun
authors.forename: So Hyun
authors.initials: SH
authors.lastname: Nam
authors.forename: Thad T
authors.initials: TT
authors.lastname: Ghim
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D020031:Epstein-Barr Virus Infections; D005260:Female; D004854:Herpesvirus 4, Human; D006801:Humans; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000378:metabolism / Q000473:pathology; D054066:Leukemia, Large Granular Lymphocytic / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D008198:Lymph Nodes / Q000473:pathology; D016896:Treatment Outcome
references.citation: Blood. 2008 May 1;111(9):4477-89
references.pmid: 18285545
references.citation: Leukemia. 2009 Jun;23(6):1139-51
references.pmid: 19194464
references.citation: Indian Pediatr. 2010 Sep;47(9):807-8
references.pmid: 21048272
references.citation: Cancer Res. 1998 Jun 15;58(12):2618-23
references.pmid: 9635588
references.citation: Cancer Genet Cytogenet. 2001 Oct 15;130(2):150-4
references.pmid: 11675136
references.citation: Int J Hematol. 2010 Dec;92(5):697-701
references.pmid: 21116747
references.citation: Jpn J Cancer Res. 2002 Nov;93(11):1270-7
references.pmid: 12460470
references.citation: Leuk Lymphoma. 2008 Jul;49(7):1392-8
references.pmid: 18452098
references.citation: Br J Haematol. 1997 Sep;98(4):922-6
references.pmid: 9326190
references.citation: Leuk Lymphoma. 2004 Dec;45(12):2427-38
references.pmid: 15621755
references.citation: Haematologica. 2002 Dec;87(12):1343-5
references.pmid: 12495907
references.citation: Ann Oncol. 2010 May;21(5):1032-40
references.pmid: 19850638
references.citation: Acta Haematol. 2008;120(4):199-206
references.pmid: 19153474
references.citation: Leukemia. 2004 Apr;18(4):763-70
references.pmid: 14961041
references.citation: Br J Haematol. 2007 Nov;139(4):532-44
references.pmid: 17916099
references.citation: J Clin Oncol. 2011 Nov 20;29(33):4410-6
references.pmid: 21990393
references.citation: Am J Pathol. 1999 Nov;155(5):1419-25
references.pmid: 10550295
references.citation: Leuk Lymphoma. 2006 Apr;47(4):715-25
references.pmid: 16690531
references.citation: Int J Hematol. 2007 Jan;85(1):18-25
references.pmid: 17261497
references.citation: Leuk Lymphoma. 1999 Jul;34(3-4):241-50
references.pmid: 10439361
references.citation: Cancer Sci. 2012 Jun;103(6):1079-83
references.pmid: 22360679
references.citation: Cancer. 1998 Aug 1;83(3):449-56
references.pmid: 9690537
references.citation: Cancer Sci. 2008 May;99(5):1016-20
references.pmid: 18294294